Annual CFO
$77.92 M
+$90.43 M+722.90%
December 31, 2023
Summary
- As of February 7, 2025, VYGR annual cash flow from operations is $77.92 million, with the most recent change of +$90.43 million (+722.90%) on December 31, 2023.
- During the last 3 years, VYGR annual CFO has risen by +$174.63 million (+180.56%).
- VYGR annual CFO is now at all-time high.
Performance
VYGR Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFO
-$27.97 M
+$3.61 M+11.44%
September 30, 2024
Summary
- As of February 7, 2025, VYGR quarterly cash flow from operations is -$27.97 million, with the most recent change of +$3.61 million (+11.44%) on September 30, 2024.
- Over the past year, VYGR quarterly CFO has dropped by -$4.21 million (-17.71%).
- VYGR quarterly CFO is now -122.35% below its all-time high of $125.16 million, reached on March 31, 2019.
Performance
VYGR Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFO
-$24.54 M
-$6.92 M-39.25%
September 30, 2024
Summary
- As of February 7, 2025, VYGR TTM cash flow from operations is -$24.54 million, with the most recent change of -$6.92 million (-39.25%) on September 30, 2024.
- Over the past year, VYGR TTM CFO has dropped by -$102.46 million (-131.50%).
- VYGR TTM CFO is now -126.03% below its all-time high of $94.28 million, reached on June 30, 2023.
Performance
VYGR TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
VYGR Cash From Operations Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +722.9% | -17.7% | -131.5% |
| 3 y3 years | +180.6% | -128.4% | -96.2% |
| 5 y5 years | +590.5% | -128.4% | -96.2% |
VYGR Cash From Operations Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +245.6% | -122.6% | +11.4% | -126.0% | +54.1% |
| 5 y | 5-year | at high | +180.6% | -122.6% | +11.4% | -126.0% | +76.7% |
| alltime | all time | at high | +180.6% | -122.3% | +11.4% | -126.0% | +76.7% |
Voyager Therapeutics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$27.97 M(-11.4%) | -$24.54 M(+39.2%) |
| Jun 2024 | - | -$31.58 M(-153.7%) | -$17.62 M(-234.3%) |
| Mar 2024 | - | $58.77 M(-347.3%) | $13.12 M(-83.2%) |
| Dec 2023 | $77.92 M(-722.9%) | -$23.76 M(+12.9%) | $77.92 M(-12.9%) |
| Sep 2023 | - | -$21.05 M(+2421.1%) | $89.44 M(-5.1%) |
| Jun 2023 | - | -$835.00 K(-100.7%) | $94.28 M(+23.0%) |
| Mar 2023 | - | $123.56 M(-1109.2%) | $76.63 M(-712.6%) |
| Dec 2022 | -$12.51 M(-76.6%) | -$12.24 M(-24.4%) | -$12.51 M(-214.4%) |
| Sep 2022 | - | -$16.21 M(-12.3%) | $10.93 M(+70.1%) |
| Jun 2022 | - | -$18.48 M(-153.7%) | $6.43 M(+192.8%) |
| Mar 2022 | - | $34.43 M(+207.5%) | $2.19 M(-104.1%) |
| Dec 2021 | -$53.52 M(-44.7%) | $11.20 M(-154.1%) | -$53.52 M(-38.3%) |
| Sep 2021 | - | -$20.71 M(-8.8%) | -$86.70 M(-4.4%) |
| Jun 2021 | - | -$22.72 M(+6.7%) | -$90.73 M(+1.7%) |
| Mar 2021 | - | -$21.29 M(-3.1%) | -$89.21 M(-7.8%) |
| Dec 2020 | -$96.72 M(-298.7%) | -$21.98 M(-11.2%) | -$96.72 M(-1.4%) |
| Sep 2020 | - | -$24.74 M(+16.7%) | -$98.10 M(+3.3%) |
| Jun 2020 | - | -$21.20 M(-26.4%) | -$94.94 M(-9.8%) |
| Mar 2020 | - | -$28.80 M(+23.3%) | -$105.29 M(-316.4%) |
| Dec 2019 | $48.67 M | -$23.36 M(+8.3%) | $48.67 M(+2.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2019 | - | -$21.58 M(-31.6%) | $47.68 M(-7.6%) |
| Jun 2019 | - | -$31.56 M(-125.2%) | $51.61 M(-14.9%) |
| Mar 2019 | - | $125.16 M(-614.1%) | $60.66 M(-481.9%) |
| Dec 2018 | -$15.89 M(-74.1%) | -$24.35 M(+38.0%) | -$15.89 M(+149.3%) |
| Sep 2018 | - | -$17.65 M(-21.6%) | -$6.37 M(+38.2%) |
| Jun 2018 | - | -$22.50 M(-146.3%) | -$4.61 M(-396.8%) |
| Mar 2018 | - | $48.61 M(-427.7%) | $1.55 M(-102.5%) |
| Dec 2017 | -$61.35 M(+44.4%) | -$14.83 M(-6.6%) | -$61.35 M(+2.9%) |
| Sep 2017 | - | -$15.89 M(-2.7%) | -$59.61 M(+10.6%) |
| Jun 2017 | - | -$16.34 M(+14.3%) | -$53.91 M(+14.0%) |
| Mar 2017 | - | -$14.29 M(+9.2%) | -$47.29 M(+11.3%) |
| Dec 2016 | -$42.48 M(-202.9%) | -$13.09 M(+28.5%) | -$42.48 M(+9.1%) |
| Sep 2016 | - | -$10.19 M(+4.9%) | -$38.95 M(+9.7%) |
| Jun 2016 | - | -$9.71 M(+2.4%) | -$35.51 M(+8.3%) |
| Mar 2016 | - | -$9.49 M(-0.7%) | -$32.78 M(-179.4%) |
| Dec 2015 | $41.30 M(-446.5%) | -$9.56 M(+41.6%) | $41.30 M(-18.8%) |
| Sep 2015 | - | -$6.75 M(-3.3%) | $50.86 M(-11.7%) |
| Jun 2015 | - | -$6.98 M(-110.8%) | $57.61 M(-10.8%) |
| Mar 2015 | - | $64.59 M | $64.59 M |
| Dec 2014 | -$11.92 M | - | - |
FAQ
- What is Voyager Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for Voyager Therapeutics?
- What is Voyager Therapeutics annual CFO year-on-year change?
- What is Voyager Therapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for Voyager Therapeutics?
- What is Voyager Therapeutics quarterly CFO year-on-year change?
- What is Voyager Therapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for Voyager Therapeutics?
- What is Voyager Therapeutics TTM CFO year-on-year change?
What is Voyager Therapeutics annual cash flow from operations?
The current annual CFO of VYGR is $77.92 M
What is the all time high annual CFO for Voyager Therapeutics?
Voyager Therapeutics all-time high annual cash flow from operations is $77.92 M
What is Voyager Therapeutics annual CFO year-on-year change?
Over the past year, VYGR annual cash flow from operations has changed by +$90.43 M (+722.90%)
What is Voyager Therapeutics quarterly cash flow from operations?
The current quarterly CFO of VYGR is -$27.97 M
What is the all time high quarterly CFO for Voyager Therapeutics?
Voyager Therapeutics all-time high quarterly cash flow from operations is $125.16 M
What is Voyager Therapeutics quarterly CFO year-on-year change?
Over the past year, VYGR quarterly cash flow from operations has changed by -$4.21 M (-17.71%)
What is Voyager Therapeutics TTM cash flow from operations?
The current TTM CFO of VYGR is -$24.54 M
What is the all time high TTM CFO for Voyager Therapeutics?
Voyager Therapeutics all-time high TTM cash flow from operations is $94.28 M
What is Voyager Therapeutics TTM CFO year-on-year change?
Over the past year, VYGR TTM cash flow from operations has changed by -$102.46 M (-131.50%)